Flower Mound, Texas/Flint, Michigan, USA — Testing of a compact cancer-treatment technology from ProTom International, Inc. (“ProTom”) demonstrated last week that the system achieves its design specification: delivering high-energy protons to isocenter at a beam intensity sufficient for standard clinical practice. The ProTom technical team measured stable and reproducible performance on the Radiance 330® Proton Therapy System at the McLaren Proton Therapy Center (“MPTC”) in Flint, Michigan.
Flower Mound, Texas/Flint, Michigan, USA —ProTom International, Inc. (“ProTom”) is proud to announce the commencement of installation of the synchrotron accelerator, a component of the Radiance 330® proton therapy system under development at the McLaren Proton Therapy Center (MPTC). The MPTC is being developed on the Flint campus of the McLaren Regional Medical Center and the Great Lakes Cancer Institute by McLaren Health Care and ProTom International. Proton beam therapy technology is growing more widespread in use as a form of radiation therapy for cancer.
Flower Mound, Texas/London, UK—ProTom International, Inc. (“ProTom”) is proud to announce it has entered into an arrangement with United Kingdom-based Advanced Proton Solutions Holdings Limited (“APS”) to provide its Radiance 330® proton therapy system for the new APS facility that will be built in the City of London.
Flower Mound, Texas/Morristown, New Jersey—ProTom International is proud to announce they have entered into an exclusive arrangement with New Jersey-based Atlantic Health System to provide the proton therapy system for the facility that will be built in its North Jersey marketplace. This facility will give Atlantic Health’s physicians and patients access to the most advanced form of treatment for many types of cancer.